AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company dedicated to developing therapies that resolve fibrosis and restore organ function. The company's business model centers on advancing a pipeline of proprietary small molecule and antibody product candidates targeting well-validated pathways, such as ALK5 (TGFβR1) and the MET receptor. As a development-stage biotech, AgomAb currently generates no operating revenue from product sales and relies on capital raised from its recent IPO and strategic investors, including Pfizer and Sanofi, to fund its research and clinical trials.
Its lead clinical asset, ontunisertib (AGMB-129), is an oral, gut-restricted inhibitor currently in Phase 2 trials for fibrostenosing Crohn's disease, a severe complication with no approved pharmacologic therapies. The company's broader pipeline also includes AGMB-447, an inhaled lung-restricted inhibitor in early clinical development for idiopathic pulmonary fibrosis (IPF), and AGMB-101, a preclinical MET receptor agonist monoclonal antibody designed to activate pathways linked to tissue repair. Headquartered in Belgium, the company holds exclusive worldwide rights to its product candidates and aims to address significant unmet medical needs in fibrotic and inflammatory diseases globally.
